Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients

ConclusionsThe serum CRP levels after first-line treatment termination could divide intermediate risk group mRCC patients into two prognostic subgroups in second-line targeted treatment setting.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research